Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2281 versus placebo in platinum-sensitive serous ovarian cancer
NL-OMON43643Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Serous Papillary Cystadenocarcinoma comparing AZD2281 with Matching placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2009; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on NL-OMON43643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43643.